Anti-UFC1 antibody [EPR15014-102],Abcam,AB189252
Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
IP, IHC-P, WB
Platform ID
BAB006750994
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data E2-like enzyme which specifically catalyzes the second step in ufmylation (PubMed : 15071506, PubMed : 29868776, PubMed : 30626644, PubMed : 34588452, PubMed : 35394863, PubMed : 36121123, PubMed : 38383789). Accepts the ubiquitin-like modifier UFM1 from the E1 enzyme UBA5 and forms an intermediate with UFM1 via a thioester linkage (PubMed : 15071506, PubMed : 29868776, PubMed : 34588452, PubMed : 38383789). Ufmylation is involved in various processes, such as ribosome recycling, response to DNA damage, interferon response or reticulophagy (also called ER-phagy) (PubMed : 27351204, PubMed : 32160526, PubMed : 35394863, PubMed : 37036982, PubMed : 38383789). See full target information UFC1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.